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Galunisertib plus gemcitabine vs. gemcitabine for first-line
treatment of patients with unresectable pancreatic cancer
Davide Melisi1, Rocio Garcia-Carbonero2, Teresa Macarulla3, Denis Pezet4, Gael Deplanque5, Martin Fuchs6, Jorg Trojan7,
Helmut Oettle8, Mark Kozloff9, Ann Cleverly10, Claire Smith11, Shawn T. Estrem12, Ivelina Gueorguieva10, Michael M. F. Lahn13,
Al Blunt14, Karim A. Benhadji15 and Josep Tabernero16
BACKGROUND: Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor
(ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. placebo in patients with
unresectable pancreatic cancer was determined.
METHODS: This was a two-part, multinational study: phase 1b was a non-randomised, open-label, multicentre, and dose-escalation
study; phase 2 was a randomised, placebo- and Bayesian-augmented controlled, double-blind study in patients with locally
advanced or metastatic pancreatic adenocarcinoma considered candidates for first-line chemotherapy with gemcitabine. Patients
were randomised 2:1 to galunisertib–gemcitabine (N= 104) or placebo-gemcitabine (N= 52). Gemcitabine dose was 1000mg/m2
QW. Primary endpoints for phases 1b and 2, respectively, were phase 2 dose and overall survival. Secondary objectives included
tolerability and biomarkers.
RESULTS: Dose-escalation suggested a 300-mg/day dose. Primary objective was met: median survival times were 8.9 and
7.1 months for galunisertib and placebo, respectively (hazard ratio [HR]= 0.79 [95% credible interval: 0.59–1.09] and posterior
probability HR < 1= 0.93). Lower baseline biomarkers macrophage inflammatory protein-1-alpha and interferon-gamma-induced
protein 10 were associated with galunisertib benefit.
CONCLUSIONS: Galunisertib–gemcitabine combination improved overall survival vs. gemcitabine in patients with unresectable
pancreatic cancer, with minimal added toxicity. Future exploration of galunisertib in pancreatic cancer is ongoing in combination
with durvalumab.
British Journal of Cancer (2018) 119:1208–1214; https://doi.org/10.1038/s41416-018-0246-z
BACKGROUND
Pancreatic cancer remains one of the most lethal and poorly
understood human malignancies.1 It has the lowest 5-year relative
survival rate among solid tumours at 8%2 and is projected to
become the second leading cause of cancer-related death by
2030 in Western countries.3 Poor prognosis in pancreatic cancer is
attributed to its early metastatic behaviour, aggressive clinical
course, and limited efficacy of chemotherapeutic treatments.4,5
The transforming growth factor-beta (TGF-β) signalling pathway
has one of the most complex and controversial roles in cancer.
TGF-β maintains homoeostasis in normal tissue; however, cancer
cells have the capacity to circumvent this suppressive influence.
Thus, pathological forms of TGF-β signalling promote tumour
growth, epithelial-to-mesenchymal transition, extracellular matrix
remodelling, stemness and evasion of immune surveillance.6
Recent whole-genome or exome sequencing confirmed TGF-β
as the most recurrently mutated signal transduction pathway in
pancreatic cancer.7
Inhibitors of TGF-β signalling have been explored in pre-clinical
models and showed enhanced anti-tumour activity in combina-
tion with gemcitabine.8 Galunisertib is the first orally bioavailable
small-molecule inhibitor of the type I TGF-β receptor (ALK5)
serine/threonine kinase to enter clinical development.9
The present study was designed to determine an appropriate
dose of galunisertib for combination with gemcitabine and to
evaluate the combination for treatment of pancreatic cancer. Safety,
pharmacokinetics, anti-tumour activity and biomarkers related to
pancreatic cancer and TGF-β signalling were also evaluated.
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METHODS
Study design and participants
This was a multinational, two-part study of oral galunisertib in
combination with gemcitabine. The first part (phase 1b) was a
non-randomised, open-label, multicentre, dose-escalation phase
in patients with solid malignancies who had not responded to
anti-cancer therapies and who were eligible for gemcitabine
therapy. The second part (phase 2) was a randomised, placebo-
and Bayesian-augmented controlled, double-blind study of
galunisertib in combination with gemcitabine vs. gemcitabine
plus placebo in patients with locally advanced or metastatic
pancreatic adenocarcinoma at first presentation or after recur-
rence following radical surgery, and who were considered
candidates for first-line chemotherapy with gemcitabine (Supple-
mentary Figure S1). Previous adjuvant or neoadjuvant gemcita-
bine was allowed. Additional details in the Supplementary
Materials.
Randomisation and masking
In phase 2, patients were randomly assigned 2:1 in the
galunisertib group vs. the placebo group, using a dynamic
randomisation procedure10 to minimise imbalance between
treatment groups using the known prognostic factors of Eastern
Cooperative Oncology Group (ECOG) performance (0 vs. 1 vs. 2),
disease stage (stages II–III vs. IV), and previous gemcitabine
treatment (adjuvant/neoadjuvant vs. no treatment), as well as
investigational site.
Procedures
Patients were treated orally twice daily (morning and evening)
with galunisertib at dose levels of 80, 160 or 300 mg/day during
phase 1b and 300mg/day or matching placebo during phase 2 for
14 days followed by 14 days off in a 28-day cycle. All patients
(phase 1b and 2) received gemcitabine via intravenous infusion at
a dose of 1000mg/m2 over 30min (~ 60min maximum) once
weekly for 7 weeks, followed by a week of rest from treatment.
Given the selected centres, this regimen of gemcitabine was the
most consensual at the time of study initiation. In order to
characterise the galunisertib pharmacokinetic profile, the initial
dose of gemcitabine was administered 7 days (±3 days) after the
first dose of galunisertib or placebo was started. Subsequent
gemcitabine cycles consisted of infusions once weekly for 3 of
every 4 weeks. Additional details in the Supplementary Materials.
Outcomes
In phase 1b, the primary objective was to determine a safe/
tolerable phase 2 dose of galunisertib in combination with
gemcitabine using a 3+ 3 dose-escalation design. The phase 2
dose was expected to achieve a pre-defined plasma galunisertib
exposure that was below levels associated with pre-clinical
cardiovascular toxicity.11
In phase 2, the primary objective was to compare overall
survival in the galunisertib and placebo groups using a Bayesian
analysis. Key secondary objectives included evaluation of the
pharmacokinetic profile and tolerability of galunisertib, compar-
ison of the treatment groups with respect to progression-free
survival and overall response rate as assessed by the investigators
and central reviewers, evaluation of biomarker changes in tumour
tissue and circulating blood, and assessment of patient-reported
pain using the Brief Pain Inventory-short form (BPI-sf) and
investigator-rated analgesic level.
Statistical analysis
Approximately 150 patients were to be randomly assigned and
the final analysis/evaluation of overall survival was to be
performed after approximately 135 events (deaths) had been
recorded or 18 months after the last patient was enroled,
whichever was sooner. The pre-specified Bayesian-augmented
design consisted of borrowing data from trials in which patients
with similar characteristics received the control treatment to
optimise treatment comparison of interest and minimise the
number of patients enroled in the concurrent control group. Using
patient-level control data from two previous randomised gemci-
tabine trials12,13 and assuming a hazard ratio [HR] of 0.7 for
survival, the study had 90% power to identify if the probability of
HR < 1 was >0.85. The type 1 error rate was 0.16.
Phase 2 efficacy analyses were conducted on the intention-to-
treat population, unless otherwise specified. This population
included all patients randomly assigned to study treatment. The
primary method of analysis for comparing overall survival
between the treatment groups used a Bayesian exponential-
likelihood model with a hierarchical random-effects distribution
on treatment effects. Additional details in the Supplementary
Materials.
Sensitivity analyses included an additional Bayesian analysis
with minimal borrowing of historical data for the control. In
addition, to assess whether unexpected bias was introduced in
this trial design, frequentist analyses of overall survival and
progression-free survival using only the data from this study were
conducted. Efficacy analyses of overall survival and progression-
free survival used Kaplan–Meier estimates and the log-rank test
stratified by randomisation factors of Eastern Cooperative
Oncology Group (ECOG) status, previous gemcitabine treatment,
and disease stage (as assessed by investigator and confirmed by
central re-read) (Supplementary Table S1). Cox proportional
hazards models also adjusted for these randomisation factors,
and stepwise analysis adjusted for multivariate factors including
ECOG, previous gemcitabine treatment, baseline liver metastasis,
sex, post-discontinuation systemic therapy and CA19-9. Overall
response rates (complete response+ partial response), clinical
benefit rates (complete response+ partial response+ stable
disease) and the exact 95% confidence interval (CI) were
estimated for each group. The comparison between groups was
done using the Fisher’s exact test. All Bayesian analyses were
carried out using the statistical software FACTS v2.4 (Berry
Consultants LLC, Austin, TX) and all other analyses were carried
out using SAS/Version 9.4.
Details on pharmacokinetics and exploratory analyses on
circulating biomarkers are available in the Supplementary
Materials.
RESULTS
This phase 1b/2 study was conducted between June 2011 and
December 2016 at 24 centres in six countries. Of the 199 patients
who entered screening for phase 2, 43 were screen-failures and
156 were randomised to study treatment, yielding 104 and 52 in
the galunisertib and placebo intention-to-treat populations,
respectively (Supplementary Figure S1). One patient assigned to
galunisertib withdrew prior to receiving treatment, and 103
patients in the galunisertib group and 52 in the placebo group
received at least one dose of study treatment (Supplementary
Figure S2).
In phase 2, 87 (56%) patients had an ECOG status of 1 and 151
(97%) patients had stage III/IV disease at study entry (Supple-
mentary Table S2). Within high-enroling centres, the dynamic
randomisation successfully ensured balance between the treat-
ments (data not shown). A median of 2.0 (range: 0–29) and 1.0
(range: 0–19) cycles were completed per patient for galunisertib
and gemcitabine, respectively. Dose omissions occurred for
galunisertib in 74 patients and for gemcitabine in 96 patients;
dose reductions occurred for galunisertib in 14 patients and
gemcitabine in 68 patients; dose discontinuations occurred
for galunisertib for 34 patients and dose delays occurred for
gemcitabine in 30 patients. A total of 84 patients died in
the galunisertib group and 48 patients died in the placebo group.
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From the primary Bayesian analysis, the median overall survival
was 7.1 months (95% credible interval [CrI]: 5.8–9.0) for the
placebo group and 8.9 months (95% CrI: 7.3–11.1) for the
galunisertib group (Fig. 1a). The posterior median HR for overall
survival was 0.79 (95% CrI: 0.59–1.09) (Table 1). The posterior
probability that the HR is <1 was 0.93, thus the primary objective
was met.
The median overall survival for the control group from the
sensitivity Bayesian analysis with minimal borrowing of historical
data for the control was higher and closer to the results using only
data from this study. The median overall survival was 7.4 months
(95% CrI: 5.7–10.0), the posterior median HR for overall survival
was 0.83 (95% CrI: 0.59–1.19) (Table 1) and the posterior
probability that the HR is <1 was 0.84, just <0.85. Frequentist
sensitivity analyses using a Cox regression model adjusted for
prognostic factors estimated the HR between the two treatment
groups as 0.86, 95% CI: 0.60–1.23 (Fig. 1b, Table 1). No significant
differences in progression-free survival were observed between
the two treatments based on either investigator assessment or
central readings (Fig. 1c, Supplementary Table S3). Previous
treatment with gemcitabine was associated with improved overall
survival (HR= 0.29, 95% CI: 0.13–0.63; data not shown).
The overall response and clinical benefit rates as measured by
central read assessment were higher for the galunisertib group,
but the differences were not statistically significant (Supplemen-
tary Table S3). Results of pain analyses are in Supplementary
Fig. S3.
Investigator-determined Common Terminology Criteria for
Adverse Events v 4.0 grade 3–4 events in phase 2 were mainly
neutrophil count decreased, anaemia and fatigue (Table 2). In the
galunisertib group vs. the placebo group, a higher percentage of
patients had grade 3–4 neutrophil count decreased (36 [35%] of
103 vs. 14 [27%] of 52) and a slightly higher percentage of patients
had grade 3–4 fatigue (13 [13%] of 103 vs. 5 [10%] of 52);
conversely, a lower percentage of patients had grade 3–4 anaemia
(12 [12%] of 103 vs. 9 [17%] of 52) and grade 3–4 platelet count
decreased (8 [8%] of 103 vs. 6 [12%] of 52). There was a similar
pattern for treatment-related grade 3–4 events (Supplementary
Table S4). Few drug-related cardiac events were observed, and
there was no significant difference in brain natriuretic peptide,
cystatin C or ejection fraction between treatment groups. Thus,
the cardiac safety was similar for both treatments. Likewise, no
apparent difference in liver toxicity was observed (Supplementary
Figure S4).
Galunisertib was rapidly absorbed into the systemic circulation,
reaching maximum concentrations typically within 1 h, and
predicted exposures were within the therapeutic window
(Supplementary Figure S5).
Baseline TGF-β1 levels were balanced between treatment
groups (Supplementary Table S2). Estimates of the HR generally
favoured patients with lower TGF-β1 at baseline (Supplementary
Figure S6), suggesting that low TGF-β1 at baseline is predictive of
response to galunisertib treatment (HR of 0.84 in patients with low
TGF-β1 levels with an OS of 10.9 months for galunisertib group vs.
7.2 months for the placebo group). Patients in the galunisertib
group with high TGF-β1 at baseline had worse survival compared
with the placebo (Supplementary Figure S7).
Assessment of the relationship between TGF-β response and
survival averaged across treatments (TGF-β responders vs. non-
responders) gave a HR of 0.75 (95% CI: 0.52–1.10) (data not
shown). For TGF-β responders, the median overall survival, pooled
across treatments, was 10.1 months (95% CI: 8.2–12.7) vs.
6.7 months (95% CI: 3.6–10.2) for TGF-β non-responders. The
percentage of patients achieving TGF-β1 reduction >20% was
slightly higher in the galunisertib group (64 [69%] of 93)
compared with the placebo group (30 [60%] of 50), with no
significant difference in overall survival: 10.9 months (95% CI:
8.2–13.7) and 9.8 months (95% CI: 7.2–15.5), respectively
(Supplementary Figure S8).
After evaluating 279 plasma proteins from 156 patients, 249
proteins were evaluable for further examination. Of these, 31
proteins were identified as prognostic factors associated with



































































































(7.3       11.1)










No. of patients Event Censored Median Survival (95% Cl)
GAL + GEM PLC + GEM




9.1 (7.4       12.2)




















No. of patients Event Censored Median Survival (95% Cl)
GAL + GEM PLC + GEM




4.1 (2.7         5.4)




Fig. 1 Kaplan–Meier estimates of survival by Bayesian vs. frequentist
analysis, with 95% Hall–Wellner confidence bands and numbers
at risk. overall survival by a Bayesian analysis, b frequentist analysis
and c progression-free survival by frequentist analysis. Data for
one patient was missing from the progression-free survival analysis.
CI=confidence interval; GAL=galunisertib; GEM=gemcitabine;
No.=number; PLC=placebo
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regressions model (Supplementary Figure S9). Additionally, 4
proteins were identified to be predictive factors associated with
survival (unadjusted for other prognostic variables) following
galunisertib treatment: interferon-gamma induced protein 10 (IP-
10) (>median at baseline HR= 0.40, 95% CI: 0.23– 0.67; ≤median
at baseline HR= 1.35, 95% CI: 0.83–2.21), follicle-stimulating
hormone (>median at baseline HR= 1.40, 95% CI: 0.83–2.37;
≤median at baseline HR 0.45, 95% CI: 0.27–0.75), macrophage
inflammatory protein-1 α (MIP-1α) (>median at baseline HR= 0.38,
95% CI: 0.22–0.66; ≤median at baseline HR= 1.02, 95% CI:
0.63–1.65) and plasminogen activator inhibitor 1 (>median at
baseline HR= 1.45, 95% CI: 0.88–2.41; ≤median at baseline HR=
0.55, 95% CI: 0.33–0.92) (p= 0.01) (Fig. 2). The levels of these
proteins did not change over time post-treatment in either group.
T-cell counts were reduced in both arms over the course of the
study; however, patients who had >50% decrease in T cells from
baseline in the first three cycles of treatment had worse overall
survival (Supplementary Figure S10).
DISCUSSION
The present study is the first randomised study of galunisertib in
pancreatic cancer. We used a randomisation favouring the
experimental group (2:1) and a pre-defined Bayesian-augmented
design to enrich the control group data with pre-existing historical
data. Using this approach, the novel combination of galunisertib
plus gemcitabine showed an improvement in survival over
gemcitabine alone. Considering the study design, the type I error
of 0.16 may be considered high relative to other phase 2 studies;
however, the primary analysis method exceeded the threshold
probability (p) required for the study to be positive quite
substantially (p [HR < 1]= 0.93, whereas 0.85 was required to
pass). Because this Bayesian-augmented design is rare in phase
2 studies, we performed sensitivity analyses to determine whether
unexpected bias was introduced, including a frequentist analysis
using only data from the study. In these supporting sensitivity
analyses, the HR ranged from 0.83 to 0.87, which still favours
galunisertib treatment. Additionally, all known prognostic factors
were well-balanced across treatment arms and therefore, minimal
bias was introduced into the study by the 2:1 randomisation. None
of the survival analyses were post hoc, but were all pre-specified in
order to legitimately consider the totality of evidence from phase
2 study results when making decisions on future development.
However, it should also be noted that the power of the study
design was reduced when using the study data alone.
Over the past decades and at the time this study started,
gemcitabine was considered the reference treatment in advanced
pancreatic cancer.10 Only recently, the combination of gemcita-
bine with the new agent nab-paclitaxel14 or the three-drug
combination regimen FOLFIRINOX11 were able to provide a
survival improvement over gemcitabine single agent. However,
these regimens are significantly more toxic than gemcitabine and
are recommended for patients who have an ECOG performance
status 0–1,12 whereas gemcitabine monotherapy remains recom-
mended for >40% of patients who have either an ECOG PS 213 or a
comorbidity profile that precludes more aggressive regimens.
Therefore, there remains a clear unmet need for the development
of gemcitabine-based regimens that are efficacious and more
tolerable than combination chemotherapy options. Considering
the overall safety profile of galunisertib plus gemcitabine did not
significantly differ from gemcitabine alone, the present findings
suggest that galunisertib plus gemcitabine may be an attractive
alternative option, especially for frail patients who are unable to
tolerate standard chemotherapy combination regimens. The
Table 2. Treatment-emergent adverse events (≥15% of any grade in phase 1b or phase 2 in either group) by CTCAE term
Phase 1b Phase 2a
Galunisertib+Gemcitabine (N=
14)
Placebo Group (N= 52) Galunisertib Group (N= 103)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Anaemia 5 (36%) 3 (21%) 1 (7%) 19 (37%) 9 (17%) 0 32 (31%) 12 (12%) 0
Neutrophil count decreased 1 (7%) 4 (29%) 2 (14%) 7 (13%) 13 (25%) 1 (2%) 6 (6%) 33 (32%) 3 (3%)
Platelet count decreased 3 (21%) 2 (14%) 1 (7%) 14 (27%) 5 (10%) 1 (2%) 35 (34%) 8 (8%) 0
Nausea 10 (71%) 0 0 16 (31%) 2 (4%) 0 36 (35%) 5 (5%) 0
Vomiting 9 (64%) 0 0 16 (31%) 4 (8%) 0 22 (21%) 4 (4%) 2 (2%)
Constipation 5 (36%) 0 0 14 (27%) 2 (4%) 0 30 (29%) 1 (1%) 0
Abdominal pain 2 (14%) 2 (14%) 0 12 (23%) 3 (6%) 0 28 (27%) 8 (8%) 1 (1%)
Diarrhoea 5 (36%) 1 (7%) 0 12 (23%) 0 0 23 (22%) 0 1 (1%)
Fever 6 (43%) 0 0 11 (21%) 1 (2%) 0 36 (35%) 3 (3%) 0
Oedema limbs 4 (29%) 0 0 11 (21%) 1 (2%) 0 21 (20%) 2 (2%) 1 (1%)
Fatigue 7 (50%) 3 (21%) 0 21 (40%) 5 (10%) 0 41 (40%) 13 (13%) 0
ALT increased 4 (29%) 0 0 2 (4%) 1 (2%) 0 6 (6%) 5 (5%) 0
AST increased 4 (29%) 0 0 2 (4%) 1 (2%) 0 4 (4%) 4 (4%) 0
Anorexia 5 (36%) 0 0 12 (23%) 1 (2%) 0 26 (25%) 4 (4%) 1 (1%)
Hypocalcemia 3 (21%) 0 0 2 (4%) 0 0 4 (4%) 2 (2%) 0
Hypoalbuminemia 5 (36%) 0 0 1 (2%) 0 0 3 (3%) 0 1 (1%)
Headache 5 (36%) 0 0 6 (12%) 0 0 6 (6%) 0 0
Myalgia 4 (29%) 0 0 1 (2%) 0 0 7 (7%) 0 0
aIn phase 2, Grade 5 events occurred that did not meet the ≥15% threshold; these included: (placebo group) 1 multiorgan failure, 1 peritoneal infection,
1 sepsis, and 1 ascites; (galunisertib group) 2 stroke, 1 pericardial effusion, 1 upper gastrointestinal haemorrhage, 1 infusion related reaction, 1 endocarditis
infection, 1 lung infection, 1 arterial injury, and 1 respiratory failure.
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Event
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positive efficacy signals for galunisertib from this present study
and its role in modulating the TGF-β pathway have prompted
interest in future validation of the efficacy of galunisertib plus
gemcitabine as well as ongoing clinical trials of galunisertib with
immunotherapeutic agents (anti-PD-L1 mAb durvalumab,
NCT02734160). The intentions of these trials are to generate
evidence for development of TGF-β pathway inhibitors in
combination with more modern therapeutic approaches.
Pancreatic cancer is characterised by a highly immunosuppres-
sive tumour microenvironment that aids rather than controls
cancer development and progression,15 and TGF-β is commonly
viewed as the most powerful immunosuppressive cytokine.16 In a
recently integrated genomic analysis of pancreatic cancer,
programmes enriched with a macrophage or T-cell co-inhibition
specific signature co-segregated with poor survival.7 Additionally,
we recently demonstrated that high plasma levels of cytokines
involved in macrophage recruitment, including MIP-1α, or FOXP3+
regulatory T cells (Treg) enrichment, including IP-10, were
negatively associated with pancreatic cancer patients’ survival.17
Thus, we examined markers associated with inflammatory and
other immunologic processes in pancreatic cancer to potentially
select patients who may benefit from TGF-β receptor inhibition.
Indeed, we identified MIP-1α and IP-10 as two of the four most
significant predictive factors for the efficacy of galunisertib plus
gemcitabine. We confirmed that patients with high circulating
levels of MIP-1α or IP-10 in the control group had a significantly
shorter overall survival. Populations with such a poor prognosis
received the greater benefit by the combination treatment with
galunisertib. T-cell subsets were not different between the arms
and patients with <50% reduction in T cells had a better overall
survival than those with greater reductions, a relationship that
may be linked to chemotherapy. Further studies addressing the
effects of targeting TGF-β signalling by galunisertib in macro-
phages and Treg cells, and the consequent potential modulation of
the immunosuppressive tumour microenvironment and chemore-
sistance in pancreatic cancer are warranted.
The pattern of treatment effect in the two TGF-β responder
groups was different. Within the responder group, median overall
survival was similar across the treatments; however, median overall
survival was improved for galunisertib plus gemcitabine in the
non-responder group. Distribution of potential prognostic factors
between the responder groups and treatment arms is under
investigation, but this study was too small to ascertain possible
reasons for the observation. Nonetheless, the association of
reduced TGF-β1 levels with improved survival has been observed
in another disease,18 suggesting that reductions in TGF-β1 levels
could represent an additional tool to assess clinical benefit even if
it may not be specific to a TGF-β inhibitor.
In conclusion, the present study indicates a positive signal of
efficacy for the combination of galunisertib and gemcitabine in
improving overall survival vs. gemcitabine in patients with
unresectable pancreatic cancer, with minimal added toxicity.
Biomarker analyses provide evidence of patient subgroups with
higher levels of cytokines recruiting macrophages or regulatory
T cells that may benefit to a greater extent from treatment with
galunisertib plus gemcitabine. Collectively, this evidence warrants
further clinical development for galunisertib in combination with
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4-PLC+GEM category > median
Fig. 2 Kaplan–Meier estimates of survival by potential predictive factor, with 95% Hall–Wellner confidence bands and numbers at risk. Overall
survival by plasma level of a follicle-stimulating hormone, b interferon-gamma induced protein 10, c macrophage inflammatory protein-1
alpha, and d plasminogen activator inhibitor 1. CL=confidence limits; GAL=galunisertib; GEM=gemcitabine; No.=number; PLC=placebo
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for patients with unresectable pancreatic cancer. One trial
evaluating galunisertib in combination with durvalumab in
pancreatic cancer is ongoing (NCT02734160).
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